Jennerex is a clinical stage company focused on the discovery and the development of targeted cancer therapeutics. Jennerex intends to enter into both development and commercialization alliances with partners to bring the first-in-class cancer therapeutics to patients world-wide.
Jennerex has proprietary technology platforms which can generate highly targeted, oncolytic virus agents for the effective treatment of cancers. Jennerex is continually reviewing new discoveries and breakthrough technologies for in-license and collaborations opportunities.
Corporate Partners:
We seek to develop value-creating corporate alliances with commercial and academic partners. These alliances will be based on cutting-edge science, innovation and complementary attributes and skill sets. We will explore alliances in the areas of product discovery, development, manufacturing and commercialization in specific geographic regions world-wide.
Corporate Alliances: Product Development and Licensing Agreement
Green Cross Corp.We currently have a product development and licensing agreement for JX-594 with Green Cross (Seoul, S. Korea) for the Korean market. Together we are focused on the development and eventual commercialization of JX-594 for liver cancers and other cancer indications in the Korean market. Green Cross is a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products.
Academic Alliances: Clinical and Discovery Research Collaborations
National Cancer Institute (Cell screening group)National Cancer Institute of Canada (Clinical Trials Group)
University of Pittsburgh (David Bartlett, Chief of Surgery, Oncology)
Institute of Cancer Research/Royal Marsden Hospital (London, UK)
Oxford University (Dept. Clinical Pharmacology)
Ottawa Health Research Institute (Ottawa, Canada)